Skip to main content
Equibles
NAUT logo

NAUT · Nautilus Biotechnology, Inc. · Webcasts, Transcripts & Audio

Track NAUT — free

Use NAUT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NAUT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.58 +0.16 (+11.27%)
Russell 2000 member Rebalance outlook locked
Market Cap
$122.51M
Shares
127.26M
Volume · Oct 1 8.46M Avg daily vol (3M) 1.49M

Nautilus Biotechnology, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Nautilus Biotechnology, Inc. (NAUT), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $ −$15.03M '25 Q2 25-07-31 LATEST · $190,000 −$14.47M '26 Q2 26-07-28
Earnings call
FY26 · Q2
2026-07-28
Nautilus Biotechnology, Inc. (NAUT) Q2 2026 Earnings Call Transcript
Positive tone Broad scale program delays Strategic pivot to Proteoform Oncology expansion and sample types
Revenue
$190,000
Diluted EPS
$-0.11
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-04-28
Nautilus Biotechnology, Inc. (NAUT) Q1 2026 Earnings Call Transcript
Confident tone Commercialization and customer engagement Voyager platform and broad-scale assay development Oncology proteoform target
Diluted EPS
$-0.12
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Nautilus Biotechnology, Inc. (NAUT) Q4 2025 Earnings Call Transcript
Confident tone Voyager instrument unveiling and early access program Proteomics platform and proteoform diversity Tau proteoform assay and collaborations
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-28
Nautilus Biotechnology, Inc. (NAUT) Q3 2025 Earnings Call Transcript
Confident tone Tau proteoform assay and collaborations Broad-scale assay configuration / technology development HUPO conference and external validation
Diluted EPS
$-0.11
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Nautilus Biotechnology, Inc. (NAUT) Q2 2025 Earnings Call Transcript
Confident tone Customer engagement and collaborations Platform reproducibility and performance Tau proteoform manuscript and scientific validation
Revenue
$
Diluted EPS
$-0.12
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-04-29
Nautilus Biotechnology, Inc. (NAUT) Q1 2025 Earnings Call Transcript
Confident tone Tau Proteoform Assay V&V Broad Scale Proteome / Platform Development Customer and Partnership Interest
Diluted EPS
$-0.13
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Nautilus Biotechnology, Inc. (NAUT) Q4 2024 Earnings Call Transcript
Positive tone Broadscale discovery Tau proteoform assay Probe optimization
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-29
Nautilus Biotechnology, Inc. (NAUT) Q3 2024 Earnings Call Transcript
Cautious tone Proteoform data and modality progress Broad scale protein quantification milestone Proteomics market opportunity
Diluted EPS
$-0.13
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-07-30
Nautilus Biotechnology, Inc. (NAUT) Q2 2024 Earnings Call Transcript
Positive tone Proteoform Technology Platform Development Metrics Product Launch Timeline
Diluted EPS
$-0.14
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-30
Nautilus Biotechnology, Inc. (NAUT) Q1 2024 Earnings Call Transcript
Confident tone U.S. HUPO conference reception Supply chain and manufacturing readiness Key opinion leader and researcher engagement
Diluted EPS
$-0.15
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Nautilus Biotechnology, Inc. (NAUT) Q4 2023 Earnings Call Transcript
Positive tone Platform Launch Timeline R&D Progress and Reproducibility Single-Molecule Protein Decoding
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-31
Nautilus Biotechnology, Inc. (NAUT) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.13
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Nautilus Biotechnology, Inc. (NAUT) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.13
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Nautilus Biotechnology, Inc. (NAUT) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.12
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
Nautilus Biotechnology, Inc. (NAUT) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-01
Nautilus Biotechnology, Inc. (NAUT) Q3 2022 Earnings Call Transcript
Diluted EPS
$-0.11
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Nautilus Biotechnology, Inc. (NAUT) Q2 2022 Earnings Call Transcript
Diluted EPS
$-0.12
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Nautilus Biotechnology, Inc. (NAUT) Q1 2022 Earnings Call Transcript
Diluted EPS
$-0.13
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Nautilus Biotechnology, Inc. (NAUT) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Nautilus Biotechnology, Inc. (NAUT) Q3 2021 Earnings Call Transcript
Diluted EPS
$-0.12
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-10
Nautilus Biotechnology, Inc. (NAUT) Q2 2021 Earnings Call Transcript
Diluted EPS
$-0.19
Audio Transcript Slides 8-K10-Q
Showing 1–21 of 21 webcasts
Key facts CIK 1808805 CUSIP 63909J108 13F (30d) 2 filings 2 filers Visit website Investor relations